Skip to main content

Table 1 Characteristics of the patients

From: Pharmacokinetics and the optimal regimen for levofloxacin in critically ill patients receiving continuous hemodiafiltration

Patient

Sex

Age (years)

Diagnosis

Weight (kg)

APACHE II

The cause of AKI

The value of Cre on admission to ICU (mg/dl)

Duration of CHDF (days)

1

Male

75

Ruptured AAA

70.7

31

Hemorrhagic shock

1.32

66

2

Male

59

OHCA

88.9

42

PCAS

0.98

5

3

Male

46

Congenital heart disease

50.0

21

Major cardiac operation

0.69

45

4

Male

58

ML

58.3

41

Drug induced

2.04

38

Mean ± SE

 

59.5 ± 6.0

-

70.0 ± 8.5

33.8 ± 4.9

-

1.25 + 0.29

38.5 + 12.7

BUN (mmol/l)

24 h CL cre (ml/min)

Q D (l/h)

Q F (l/h)

Predictive CL total (l/h)

Calculated optimal dose of LVFX (mg)

42

3.4

1.0

2.0

4.0

200

43

0.9

1.0

2.0

4.0

200

40

-

1.0

2.0

-

-

32

3.4

0.5

1.5

2.9

145

39.3 ± 5.0

2.6 ± 0.8

0.86 + 0.13

1.88 + 0.13

3.6 ± 0.4

182 + 18.3

  1. AAA abdominal aortic aneurysm, OHCA out-of-hospital cardiac arrest, ML malignant lymphoma, APACHE II Acute Physiology and Chronic Health Evaluation II score, AKI acute kidney injury, PCAS post-cardiac arrest syndrome, Cre creatinine, ICU intensive care unit, CHDF continuous hemodiafiltration, BUN blood urea nitrogen, CLcre creatinine clearance, CLtotal total clearance, QD dialysate flow, QF ultrafiltrate flow, LVFX levofloxacin, SE standard error.